Savara/$SVRA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Savara
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Ticker
$SVRA
Sector
Primary listing
Employees
59
Headquarters
Website
Savara Metrics
BasicAdvanced
$945M
-
-$0.51
0.40
-
Price and volume
Market cap
$945M
Beta
0.4
52-week high
$4.51
52-week low
$1.89
Average daily volume
1.5M
Financial strength
Current ratio
11.079
Quick ratio
10.859
Long term debt to equity
24.612
Total debt to equity
24.686
Profitability
EBITDA (TTM)
-116.493
Management effectiveness
Return on assets (TTM)
-48.04%
Return on equity (TTM)
-99.30%
Valuation
Price to book
6.91
Price to tangible book (TTM)
7.65
Price to free cash flow (TTM)
-8.545
Free cash flow yield (TTM)
-11.70%
Free cash flow per share (TTM)
-0.462
Growth
Earnings per share change (TTM)
22.73%
3-year earnings per share growth (CAGR)
25.87%
What the Analysts think about Savara
Analyst ratings (Buy, Hold, Sell) for Savara stock.
Bulls say / Bears say
H.C. Wainwright upgraded Savara to Buy with a $5.00 price target on August 15, 2025, following a Type A meeting with the FDA that aligned on CMC requirements and improved the regulatory outlook ahead of the BLA resubmission (Investing.com)
Savara secured a $75 million non-dilutive royalty funding agreement with RTW Investments, providing launch financing contingent on FDA approval and strengthening its balance sheet without equity dilution (Reuters via Stockopedia)
As of March 31, 2025, Savara held approximately $172.5 million in cash and short-term investments, extending its cash runway into the second half of 2027, which provides financial stability ahead of potential commercialization (GuruFocus)
FDA issued a Refusal to File letter on May 27, 2025, citing incomplete CMC data and delaying substantive review of the MOLBREEVI BLA, which could push back the approval timeline and heighten regulatory uncertainty (The Pharmaletter)
Savara’s net loss widened to $30.4 million in Q2 2025 from $22.2 million a year earlier, underscoring significant operating losses and elevated R&D and G&A spending ahead of any product revenue (Reuters via Tiger Brokers)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
Savara Financial Performance
Revenues and expenses
Savara Earnings Performance
Company profitability
Savara News
AllArticlesVideos
SVRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SVRA
Newsfile Corp19 hours ago
SVRA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SVRA
Newsfile Corp2 days ago
Deadline Soon: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Business Wire2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Savara stock?
Savara (SVRA) has a market cap of $945M as of November 08, 2025.
What is the P/E ratio for Savara stock?
The price to earnings (P/E) ratio for Savara (SVRA) stock is 0 as of November 08, 2025.
Does Savara stock pay dividends?
No, Savara (SVRA) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next Savara dividend payment date?
Savara (SVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Savara?
Savara (SVRA) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.